Report Detail
Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
- RnM3839046 |
- 28 November, 2019 |
- Global |
- 123 Pages |
- GlobalData |
- Medical Devices & Consumables
Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
Summary
GlobalData's Medical Devices sector report, “Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Rapid Tests & Point of Care (POC) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Retrovirus Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Retrovirus Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Retrovirus Rapid Tests & Point of Care (POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Retrovirus Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
- 1.1 List of Tables 5
- 1.2 List of Figures 8
2 Introduction 9
- 2.1 Retrovirus Rapid Tests & Point of Care (POC) Overview 9
Retrovirus Rapid Tests & Point of Care are the rapid diagnostic tests used to detect the HIV 1 and HIV 2 (human immunodeficiency virus) viruses and generate results immediately in a limited resource setting. 9
3 Products under Development 10
- 3.1 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development 10
- 3.2 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Territory 11
- 3.3 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Regulatory Path 12
- 3.4 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Estimated Approval Date 13
4 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products under Development by Companies 14
- 4.1 Retrovirus Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 14
- 4.2 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development 16
5 Retrovirus Rapid Tests & Point of Care (POC) Companies and Product Overview 18
- 5.1 Access Bio Inc Company Overview 18
- 5.1.1 Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 18
- 5.2 Akers Biosciences Inc Company Overview 19
- 5.2.1 Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 19
- 5.3 Aldatu Biosciences Inc Company Overview 20
- 5.3.1 Aldatu Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 20
- 5.4 Alere Inc Company Overview 21
- 5.4.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 21
- 5.5 Altratech Ltd Company Overview 22
- 5.5.1 Altratech Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
- 5.6 BBB Technologies Inc Company Overview 23
- 5.6.1 BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 23
- 5.7 Beijing Wantai Biological Pharmacy Enterprise Co Ltd Company Overview 24
- 5.7.1 Beijing Wantai Biological Pharmacy Enterprise Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
- 5.8 Binx Health Inc Company Overview 25
- 5.8.1 Binx Health Inc Pipeline Products & Ongoing Clinical Trials Overview 25
- 5.9 Bio-AMD Inc Company Overview 26
- 5.9.1 Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview 26
- 5.10 Biocartis Group NV Company Overview 27
- 5.10.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 27
- 5.11 BioHelix Corp Company Overview 28
- 5.11.1 BioHelix Corp Pipeline Products & Ongoing Clinical Trials Overview 28
- 5.12 Calypte Biomedical Corporation Company Overview 30
- 5.12.1 Calypte Biomedical Corporation Pipeline Products & Ongoing Clinical Trials Overview 30
- 5.13 Centre International de Reference Chantal Biya Company Overview 32
- 5.13.1 Centre International de Reference Chantal Biya Pipeline Products & Ongoing Clinical Trials Overview 32
- 5.14 Cepheid Company Overview 33
- 5.14.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 33
- 5.15 Chembio Diagnostic Systems Inc Company Overview 35
- 5.15.1 Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 35
- 5.16 CrossLife Technologies Inc Company Overview 38
- 5.16.1 CrossLife Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38
- 5.17 Daktari Diagnostics, Inc. Company Overview 39
- 5.17.1 Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
- 5.18 Diagnostics For All Inc Company Overview 40
- 5.18.1 Diagnostics For All Inc Pipeline Products & Ongoing Clinical Trials Overview 40
- 5.19 Diagnostics for the Real World (Europe) Ltd Company Overview 41
- 5.19.1 Diagnostics for the Real World (Europe) Ltd Pipeline Products & Ongoing Clinical Trials Overview 41
- 5.20 Endeavor Sciences Inc Company Overview 42
- 5.20.1 Endeavor Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 42
- 5.21 Epinex Diagnostics Inc Company Overview 43
- 5.21.1 Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 43
- 5.22 ERBA Molecular Ltd Company Overview 44
- 5.22.1 ERBA Molecular Ltd Pipeline Products & Ongoing Clinical Trials Overview 44
- 5.23 GAIA Medical Institute LLC Company Overview 45
- 5.23.1 GAIA Medical Institute LLC Pipeline Products & Ongoing Clinical Trials Overview 45
- 5.24 genedrive plc Company Overview 46
- 5.24.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 46
- 5.25 Group K Diagnostics Company Overview 47
- 5.25.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 47
- 5.26 HeatFlow Technologies Inc Company Overview 48
- 5.26.1 HeatFlow Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 48
- 5.27 Imperial College London Company Overview 49
- 5.27.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49
- 5.28 Jinvator Bio Med GmbH Company Overview 50
- 5.28.1 Jinvator Bio Med GmbH Pipeline Products & Ongoing Clinical Trials Overview 50
- 5.29 Johns Hopkins University Company Overview 51
- 5.29.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 51
- 5.30 Labsystems Diagnostics Oy Company Overview 52
- 5.30.1 Labsystems Diagnostics Oy Pipeline Products & Ongoing Clinical Trials Overview 52
- 5.31 Micronics Inc Company Overview 53
- 5.31.1 Micronics Inc Pipeline Products & Ongoing Clinical Trials Overview 53
- 5.32 Molbio Diagnostics Pvt Ltd Company Overview 55
- 5.32.1 Molbio Diagnostics Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 55
- 5.33 Nanobiosym Inc Company Overview 56
- 5.33.1 Nanobiosym Inc Pipeline Products & Ongoing Clinical Trials Overview 56
- 5.34 NeuMoDx Molecular Inc Company Overview 57
- 5.34.1 NeuMoDx Molecular Inc Pipeline Products & Ongoing Clinical Trials Overview 57
- 5.35 Newmark Diagnostics LLC Company Overview 58
- 5.35.1 Newmark Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 58
- 5.36 Northwestern University Company Overview 59
- 5.36.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 59
- 5.37 Orangelife Company Overview 60
- 5.37.1 Orangelife Pipeline Products & Ongoing Clinical Trials Overview 60
- 5.38 Osel Inc Company Overview 61
- 5.38.1 Osel Inc Pipeline Products & Ongoing Clinical Trials Overview 61
- 5.39 QuantuMDx Group Ltd Company Overview 62
- 5.39.1 QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
- 5.40 Quidel Corp Company Overview 63
- 5.40.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 63
- 5.41 Radisens Diagnostics Ltd Company Overview 64
- 5.41.1 Radisens Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 64
- 5.42 Rheonix Inc Company Overview 65
- 5.42.1 Rheonix Inc Pipeline Products & Ongoing Clinical Trials Overview 65
- 5.43 Roche Diagnostics International Ltd Company Overview 66
- 5.43.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
- 5.44 Sedia Biosciences Corp Company Overview 67
- 5.44.1 Sedia Biosciences Corp Pipeline Products & Ongoing Clinical Trials Overview 67
- 5.45 TheoremDx Inc Company Overview 69
- 5.45.1 TheoremDx Inc Pipeline Products & Ongoing Clinical Trials Overview 69
- 5.46 Trinity Biotech Plc Company Overview 70
- 5.46.1 Trinity Biotech Plc Pipeline Products & Ongoing Clinical Trials Overview 70
- 5.47 University of Washington Company Overview 71
- 5.47.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71
- 5.48 UrSure Inc Company Overview 72
- 5.48.1 UrSure Inc Pipeline Products & Ongoing Clinical Trials Overview 72
- 5.49 Wave 80 Biosciences Inc Company Overview 73
- 5.49.1 Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 73
- 5.50 Yaathum Biotech Pvt Ltd Company Overview 75
- 5.50.1 Yaathum Biotech Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 75
6 Retrovirus Rapid Tests & Point of Care (POC) - Recent Developments 76
- 6.1 Nov 04, 2019: Chembio Diagnostics receives WHO Prequalification Approval for HIV Self-Test 76
- 6.2 Oct 30, 2019: Quidel reports third quarter 2019 financial results 76
- 6.3 Oct 17, 2019: Chembio Diagnostics receives WHO prequalification approval for Malaysia facility 78
- 6.4 Oct 16, 2019: Trinity Biotech announces results for Q3, 2019 78
- 6.5 Oct 15, 2019: Johnson & Johnson reports 2019 Third-Quarter Results 80
- 6.6 Sep 30, 2019: Johnson & Johnson appoints Carlton Lawson to area Managing Director, Consumer, Northern Europe 81
- 6.7 Sep 19, 2019: INSTI now available for expanded point-of-care use in Canada 81
- 6.8 Sep 16, 2019: Omega Diagnostics Group: Update on VISITECT CD4 Advanced Disease 82
- 6.9 Sep 05, 2019: Biocartis announces H1 2019 results 83
- 6.10 Aug 20, 2019: First purchase order for VISITECT CD4 advanced disease test 88
7 Appendix 120
- 7.1 Methodology 120
- 7.2 About GlobalData 123
- 7.3 Contact Us 123
Summary:
Get latest Market Research Reports on Retrovirus Rapid Tests & Point of Care (POC). Industry analysis & Market Report on Retrovirus Rapid Tests & Point of Care (POC) is a syndicated market report, published as Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019. It is complete Research Study and Industry Analysis of Retrovirus Rapid Tests & Point of Care (POC) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
